Articles producció científica> Medicina i Cirurgia

Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of Armolipid Plus with berberine

  • Datos identificativos

    Identificador: PC:1509
    Autores:
    Rosa María VallsIsabel De Castro-OrósRosa SolàAngel BreaPilar MozasJose PuzoMiguel Pocoví
    Resumen:
    Background: Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with red yeast, berberine, coenzyme Q10, folic acid, and astaxanthin. It has been shown to be effective in reducing plasma LDL cholesterol (LDLc) levels. In the multicenter randomized trial NCT01562080, there was large interindividual variability in the plasma LDLc response to AP supplementation. We hypothesized that the variability in LDLc response to AP supplementation may be linked to LDLR and PCSK9 polymorphisms. Material and Methods: We sequenced the LDLR 30 and 50 untranslated regions (UTR) and the PCSK9 50 UTR of 102 participants with moderate hypercholesterolemia in trial NCT01562080. In this trial, 50 individuals were treated with AP supplementation and the rest with placebo. Results: Multiple linear regression analysis, using the response of LDLc levels to AP as the dependent variable, revealed that polymorphisms rs2149041 (c.-3383C>G) in the PCSK9 50 UTR and rs14158 (c.∗52G>A) in the LDLR 30 UTR explained 14.1%and 6.4%, respectively, of the variability after adjusting for gender, age, and BMI of individuals. Combining polymorphisms rs2149041 and rs14158 explained 20.5%of this variability (p < 0.004). Conclusions: Three polymorphisms in the 30 UTR region of LDLR, c.∗52G>A, c.∗504G>A, and c. ∗773A>G, and two at the 50 UTR region of PCSK9, c.-3383C>G and c.-2063A>G, were associated with response to AP. These results could explain the variability observed in the response to berberine among people with moderate hypercholesterolemia, and they may be useful in identifying patients who could potentially benefit from supplementation with AP.
  • Otros:

    Autor según el artículo: Rosa María Valls; Isabel De Castro-Orós; Rosa Solà; Angel Brea; Pilar Mozas; Jose Puzo; Miguel Pocoví
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: VALLS ZAMORA, ROSA MARIA; Isabel De Castro-Orós; Rosa Solà; Angel Brea; Pilar Mozas; Jose Puzo; Miguel Pocoví
    Palabras clave: Està en blanc
    Resumen: Background: Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with red yeast, berberine, coenzyme Q10, folic acid, and astaxanthin. It has been shown to be effective in reducing plasma LDL cholesterol (LDLc) levels. In the multicenter randomized trial NCT01562080, there was large interindividual variability in the plasma LDLc response to AP supplementation. We hypothesized that the variability in LDLc response to AP supplementation may be linked to LDLR and PCSK9 polymorphisms. Material and Methods: We sequenced the LDLR 30 and 50 untranslated regions (UTR) and the PCSK9 50 UTR of 102 participants with moderate hypercholesterolemia in trial NCT01562080. In this trial, 50 individuals were treated with AP supplementation and the rest with placebo. Results: Multiple linear regression analysis, using the response of LDLc levels to AP as the dependent variable, revealed that polymorphisms rs2149041 (c.-3383C>G) in the PCSK9 50 UTR and rs14158 (c.∗52G>A) in the LDLR 30 UTR explained 14.1%and 6.4%, respectively, of the variability after adjusting for gender, age, and BMI of individuals. Combining polymorphisms rs2149041 and rs14158 explained 20.5%of this variability (p < 0.004). Conclusions: Three polymorphisms in the 30 UTR region of LDLR, c.∗52G>A, c.∗504G>A, and c. ∗773A>G, and two at the 50 UTR region of PCSK9, c.-3383C>G and c.-2063A>G, were associated with response to AP. These results could explain the variability observed in the response to berberine among people with moderate hypercholesterolemia, and they may be useful in identifying patients who could potentially benefit from supplementation with AP.
    Grupo de investigación: Unitat de Recerca de Lípids i Arteriosclerosi
    Áreas temáticas: Health sciences Ciencias de la salud Ciències de la salut
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1932-6203
    Identificador del autor: N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Fecha de alta del registro: 2016-05-02
    Volumen de revista: 11
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150785
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1371/journal.pone.0150785
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2016
    Tipo de publicación: Article Artículo Article
  • Palabras clave:

    HIPERCOLESTEROLÈMIA
    Està en blanc
    Health sciences
    Ciencias de la salud
    Ciències de la salut
    1932-6203
  • Documentos:

  • Cerca a google

    Search to google scholar